Mozavaptan
From Self-sufficiency
| File:Mozavaptan structure.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
N-[4-(5-Dimethylamino-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]-2-methylbenzamide | |
| Clinical data | |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 137975-06-5 |
| ATC code | none |
| PubChem | CID 119369 |
| Chemical data | |
| Formula | C27H29N3O2 |
| Molar mass | 427.53 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.
References
- H. Spreitzer (November 20, 2006). "Neue Wirkstoffe - Conivaptan". Österreichische Apothekerzeitung (in German) (24/2006).
- Prous Science: Molecule of the Month November 2006
| 40px | This antihypertensive-related article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Drugs with non-standard legal status
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- CS1 maint: Unrecognized language
- Antihypertensive agent stubs
- 2Fix
- Diuretics
- Hormonal agents
- Benzanilides
- Amides
- Benzazepines
